Akeso Biopharma

Akeso, Inc. is a Chinese biopharmaceutical company focused on developing innovative antibody therapies. The company advances an IO2.0 + ADC2.0 strategy, developing bispecific antibodies and antibody-drug conjugates for cancer treatment. Recent pipeline milestones include AK157D1 for solid tumors and ivonescimab for lung cancer.

Source: https://www.akesobio.com/en

penpulimabPenpulimab-kcqx

PD-1 checkpoint inhibitor

Penpulimab-kcqx is a PD-1 checkpoint inhibitor from Akeso Biopharma for non-keratinizing nasopharyngeal carcinoma. It is used with platinum chemotherapy plus gemcitabine as first-line treatment of recurrent or metastatic disease, and alone after platinum-based chemotherapy and at least one later line of therapy.

Penpulimab is a monoclonal antibody given by intravenous infusion that targets PD-1, an off-switch expressed on T cells. Many cancers display the liga

1 medicine explained